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INTRODUCTION
Gingival overgrowth (GO) has always been a major concern for all the clinicians in the field of dentistry in terms of diagnosis, prognosis, treatment, and prevention of its recurrence. GO, being multifactorial, can be broadly classified into inflammatory, drug-induced, conditioned, and neoplastic enlargements. Drug-induced GO (DIGO) is a well-documented, major unwanted side effect of certain drugs, mainly antiepileptics, calcium channel blockers (CCB), and immunosuppressants [1] . Amlodipine is a third-generation dihydropyridine CCB used in the management of both hypertension and angina. In 1993, Ellis et al [2] first reported Amlodipine-induced GO (AIGO). The prevalence of AIGO has been shown to be between 1.7% and 3.3% [3] . Plasma cell granuloma (PCG) is a non-neoplastic lesion characterized by the predominance of polyclonal plasma cells. Bhaskar et al [4] were the first to report the cases of PCG in 1968. There is no sex and age predilection associated with this lesion. The precise etiopathogenesis is uncertain. However, some authors have suggested PCG as a hyperreactive lesion to allergens/ idiopathic antigens, long-standing periodontitis, and periradicular inflammation [5] . Although PCG most commonly affects the lungs [6] , other organs like the orbit and paranasal sinuses may also be involved frequently [7] . It has also been reported in the tonsils [8] , tongue [9] , lips, oral mucosa [10] , periodontal tissues, and rarely in the gingiva [11] [12] [13] [14] [15] . The gingival PCG is exceedingly rare. Clinically, it presents as a nodular, polypoidal mass with a smooth surface. It has no systemic symptoms. Routine laboratory investigations are normal, and microbiological culture results are negative. Some oral lesions have shown infiltrative margins on radiographs, giving the appearance of a malignant tumor [16] . Recently, this lesion has been reported in patients receiving Cyclosporine [17] and Amlodipine [18] . The clinical diagnosis of GO becomes cumbersome if more than one factor responsible for GO present in the same patient. Hence, careful and confirmatory diagnosis becomes utmost important for the establishment of an accurate prognosis and management of the lesion. In the present case report, we want to discuss a rare case of gingival PCG in the maxillary anterior region in a hypertensive patient on Amlodipine therapy.
CASE REPORT
A 60-year-old female patient reported to the Department of Periodontology, Govt. College of Dentistry, Indore Madhya Pradesh, India, with the chief complaint of swollen gums in upper front teeth region since one year previously. Also, she reported pain and discomfort upon mastication. The history of the present illness revealed that the growth was present since one year ago, gradually increased in size, is associated with difficulty on mastication, and interferes with maintenance of oral hygiene. On taking a proper medical history, the patient was found to be hypertensive and was on Amlodipine therapy (20 mg 1 Once a day orally) for the last 20 years. The dental history mentions extraction of some teeth due to periodontitis. On periodontal examination, GO was apparent from the distal aspect of the maxillary right canine to the distal aspect of the left lateral incisor on both buccal and palatal aspects. The overgrowth was sessile with a smooth surface and approximately 2×2×3 cm 3 in size. Bleeding on probing was positive in relation to the overall dentition including the sulcular epithelium of the region of the GO (Fig.  1 ). The GO was also observed in relation to the mandibular right lateral incisor. Moderately deep periodontal pockets were present in the rest of the dentition with the presence of abundant supragingival and subgingival local factors. The patient was edentulous in the mandibular arch, except for the mandibular right lateral incisor and right first premolar. No gingival enlargement was seen associated with the edentulous region. Three-degree tooth mobility (Miller's index) was present in relation to the left upper central incisor with a probing pocket depth of 8 mm. Pathological migration of teeth in the maxillary anterior region was evident, and bleeding on probing was positive. On palpation, GO was firm in consistency and was fixed to the underlying structures. It was non-tender, non-pulsatile, non-fluctuant, and non-compressible in nature. Severe horizontal bone loss in relation to the maxillary anterior teeth along with moderate generalized bone loss in the rest of the dentition was evident on the panoramic radiograph ( Fig. 2) . A provisional diagnosis of AIGO, combined gingival overgrowth, and irritation fibroma was made based on the clinical findings. After the completion of phase I therapy, an excisional biopsy along with extraction of the left upper central incisor was planned, and the treatment was explained comprehensively to the patient. Amlodipine was substituted by another antihypertensive drug, angiotensin-convertingenzyme inhibitor (ACE inhibitor), after consultation with the responsible physician. With the patient's consent and after necessary hematologic investigations, surgical excision was performed under local anesthesia ( Fig. 3A  and 3B ). The excised tissue sample was fixed in 10% formalin and was sent for histopathological examination. Antibiotics and analgesics were prescribed for the patient for five days. 0.12% Chlorhexidine mouthwash twice a day was advised. Oral hygiene instructions were reinforced. The sections stained with Hematoxylin and eosin (H&E) revealed the presence of proliferative stratified squamous epithelium at the surface with elongated rete ridges. Areas of ulceration were noted.
The underlying stroma was fibrocellular with bundles of collagen intersecting, patchy distribution of chronic inflammatory cells characterized predominantly by mature plasma cells, lymphocytes, and occasional eosinophils, suggesting a plasma cell lesion (Fig. 4A ). This was further confirmed by performing immunohistochemistry (IHC) on the biopsy sample for Kappa (Κ) and Lambda (λ) light chains. IHC staining of the tissue section showed notable cytoplasmic positivity for both Κ and λ light chains (Κ chains more than λ chains; Fig.  4B and 4C ). All these features suggest polyclonal plasma cell proliferation, confirming the histopathological features.
Therefore, a confirmatory diagnosis of PCG was made based on the clinical, histopathological, and IHC analysis. Healing was uneventful after surgery. The patient was followed every week for a month and then every 3 months and thereafter for a period of 15 months. There was a significant improvement in the gingival status of the overall dentition as a result of thorough and strict plaque control measures at subsequent maintenance visits in the entire duration of the supportive periodontal therapy. No evidence of recurrence of the growth was seen during the recall visits in a period of 15 months (Fig. 5 ).
DISCUSSION
The present case report discusses gingival PCG and emphasizes the importance of a confirmatory diagnosis for GO. Since the patient was a known hypertensive, was on Amlodipine therapy since 20 years previously, and had generalized periodontal disease, the clinical picture of the GO has inclined us towards the provisional diagnosis of drug-induced GO, combined overgrowth, and fibroma. The histopathological examination of the biopsy revealed profound and diffuse mature plasma cell infiltration, which was further confirmed by IHC. The presence of positivity for Κ and λ (2:1) light chains has led us to the confirmatory diagnosis of PCG. The histopathology of DIGO is characterized by the presence of abundant hyperplastic connective tissue and epithelium, and excess of amorphous extracellular matrix. Reactive fibroma is histologically characterized by the presence of a dense fibrous connective tissue [19] . PCG is also known as inflammatory myofibrohistiocytic proliferation, inflammatory myofibroblastic tumor, Inflammatory pseudotumor, and xanthomatous pseudotumor [19] . [11] . IHC determines the polyclonality of the PCG lesion; in a reactive lesion, K chains are greater than λ chains, and the K to λ light chain ratio is 2:1, whereas in case of a neoplastic lesion, the ratio may be greater than 10:1 or 1:10 [12]. Few authors have documented cases of PCG in patients on other medications. Two cases of PCG in patients on Cyclosporine drug therapy have been mentioned in the literature [17] . Both cases revealed strong immunoreactivity for interleukin-6 (IL-6) and overexpression of phospholipase-C ϒ1. IL-6 is known to play an important role in the differentiation and activation of plasma cells. The authors explained this as a possible mechanism for rich plasma cell infiltration in cyclosporine-induced plasma cell GO. A similar case of PCG in a patient on Amlodipine has been reported recently; the authors have considered a multifactorial etiology for Amlodipine-induced PCG and have emphasized on the drug/cellular interaction as a possible mechanism [18] . Post-excision healing was satisfactory in the maxillary anterior region. GO in other areas of the dentition decreased significantly along with a noticeable decrease in the overgrowth in the mandibular right lateral incisor area (Fig. 5C ). This can be attributed to the combination of non-surgical periodontal therapy. Although authors have suggested PCG as a hyper-reactive lesion to allergens/idiopathic antigens, longstanding periodontitis, and periradicular Front Dent, Vol. 16 
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inflammation [5] , the accurate etiology could not be established yet. In the present case, we could not definitively identify any allergic factor, and we suggest long-standing inflammation and irritation as possible etiology since several local factors and mobile teeth were present in the area of GO.
CONCLUSION
The present case reinforces that all GOs should be comprehensively examined (histopathological and/or advanced confirmatory investigation), regardless of the clinical appearance, surgical management, and treatment success rate.
